Clinical trial
GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in…
NCT00300105 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00300105 |
|---|---|
| Title | GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes |
| Official title | A Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar Therapy in Patients With Type 2 Diabetes |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | Tesaglitazar |
| Enrollment | 400 |
| Start date | Oct 1, 2005 |
| Completion | Dec 1, 2006 |
| First posted | Mar 8, 2006 |
| Last update posted | Mar 17, 2008 |
| Countries | Belgium, Hong Kong, Hungary, Italy, Malaysia, Philippines, Poland, Slovakia, South Africa, Thailand |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: